Canadian diagnostics company Nanostics released interim trial data showing its ClarityDX prostate test is 147 percent more specific than the prostate-specific antigen (PSA) blood test for predicting clinically significant prostate cancer.

A new study evaluating Cardiologs’ deep learning tool for identifying patients at risk for atrial fibrillation (AFib) showed that it outperformed regular 12-lead electrocardiogram (ECG) testing.

Miami, Fla.-based DermaSensor said two studies of its handheld skin cancer detection device — which could become the first FDA-cleared device of its kind for use by primary care physicians — have demonstrated the device’s efficacy.